Raloxifene decreases cell viability and migratory potential in prostate cancer cells (LNCaP) with GPR30/GPER1 involvement.

Giovanna Cassone SalataCristiane Figueiredo PinhoAndré T A G de FreitasAriana Musa AquinoLuis Antonio JustulinLeonardo Oliveira MendesBianca F GonçalvesFlávia Karina DelellaWellerson Rodrigo Scarano

Published in: The Journal of pharmacy and pharmacology (2019)

Raloxifene was able to modulate GPER1 in LNCaP prostate tumour cells, decreasing cell viability and their migratory potential.

Keyphrases

induced apoptosis
estrogen receptor
prostate cancer
human health
cell cycle arrest
risk assessment
benign prostatic hyperplasia
cell proliferation
signaling pathway